Use of cookies on this website: This website uses cookies to give you the best user experience, for analytics, and improvement of functionalities of this website and third party sites. You can learn more about our use of cookies and similar technologies and your choices by reviewing our Cookies Policy. By clicking "I agree" you agree to our use of cookies.

Anticalin proteins contain rationally diversified amino acids within these four loops and ligand-binding areas of the beta barrel, while maintaining the integrity of the lipocalin structure.

This diversity has yielded a drug class that:

provides a coveted specificity and affinity against a wide spectrum of targets;

exhibits the safety of an endogenous protein performing an endogenous function;

is durable, creating greater flexibility of formulation and delivery; and

tightly binds a target as a monovalent molecule, overcoming the complications of multivalent binding approaches, when agonist receptor cross-linking is therapeutically counter-productive.

To obtain a specific Anticalin protein, Pieris applies its significant protein engineering know-how and the breadth of its exclusive Anticalin libraries. The company's suite of proprietary phage display libraries has been created by rationally diversifying the lipocalin regions that are responsible for ligand binding, with different libraries applied to different types of targets. Once defined, a novel Anticalin protein can be produced in any number of bacterial expression systems, including Wacker Biosolutions’ ESETEC® system, with which Pieris has achieved impressive yields. Using best-in-class bacterial production remains constant from the earliest stages of drug discovery through to and including GMP, ensuring quality as well as cost effective production.

Pieris Drug Pipeline

Pieris pipeline includes multiple fully proprietary as well as partnered programs in a number of different therapeutic areas. Our most advanced Anticalin program PRS-080 (hepcidin antagonist to treat anemia), our advanced respiratory program PRS-060 (1st-in-class inhaled IL4Ra antagonist to treat asthma) and several of our immuno-oncology (IO) multispecific programs (PRS-300 series), led by PRS-343 (a HER2/4-1BB bispecific), are examples of our fully proprietary programs. As we continue to build our IO and Respiratory franchises, we aim to ultimately develop Pieris into a fully-integrated pharmaceutical company by retaining commercial rights to several of these programs in major markets. For this purpose, we are also joining forces with other pharmaceutical companies, as exemplified by our strategic co-development IO alliance with Servier, with PRS-332 (PD1-based dual checkpoint inhibitor) as the lead program of this collaboration, to which we retain full US rights.